Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
Eligible age
18–80 yrs
Accepts
Men
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.
Sponsor: Albany Medical College
You may qualify if…
- ✓ Male patients age between 18-80 years old with a screening PSA \> 3 ng/ml being considered for additional diagnostic testing (e.g., MRI, biopsy)
- ✓ Normal digital rectal examination within the past two years. A documented normal digital rectal examination by another physician or advanced practice provider (NP, PA, etc) is acceptable.
- ✓ No clinical symptoms concerning for acute urinary tract infection (e.g. dysuria, malodorous urine, positive urine culture)
You may not qualify if…
- ✕ History of hypersensitivity or allergy to ibuprofen or NSAIDs.
- ✕ History of peptic ulcer disease, GI bleeding or NSAIDs induced GI adverse events
- ✕ Known bleeding disorders
- ✕ Known severe chronic kidney disease: eGFR \< 30 mL/min/1.73 m2
- ✕ Heart failure, significant heart disease
- ✕ Poorly controlled hypertension
- ✕ Active urinary tract infections or bacteriuria
- ✕ Concomitant use of 5-alpha reductase inhibitors (finasteride, dutasteride) unless patient has been taking it for at least 6 months
Where it's recruiting
Source: ClinicalTrials.gov · NCT05629494 · last updated 2024-10-18